Larimar Therapeutics terminates at-the-market equity facility with Guggenheim; no shares ever sold

Larimar Therapeutics, Inc.

Terminated Sales Agreement with Guggenheim Securities effective Feb 13, 2024.
Agreement permitted up to $50M in at-the-market common stock offerings.
No shares of common stock were ever sold under the agreement.
Original agreement date was November 10, 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Larimar Therapeutics, Inc. terminated Sales Agreement with Guggenheim Securities, LLC valued at Aggregate offering price of up to $50,000,000; no shares sold under the agreement (effective 2024-02-13).

Action: termination
Agreement: atm program
Counterparty: Guggenheim Securities, LLC
Value: Aggregate offering price of up to $50,000,000; no shares sold under the agreement
Effective: 2024-02-13

Exact text from the filing

On February 13, 2024, Larimar Therapeutics, Inc. (the “ Company ”) gave notice to terminate the Sales Agreement that the Company entered into with Guggenheim Securities, LLC on November 10, 2022 (the “ Sales Agreement ”). Termination of the Sales Agreement was effective February 13, 2024.

View on SEC.gov

Browse all material agreements →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-014919

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.